SBIR/STTR Research Award

Photodynamic Blood Product Decontamination

Award identifier e44897d8d77f46d35856baa326e4e67973711b7ecb046c72c3a6ad2a914494b9Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$265,551

Program and phase

STTR · Phase I

Award year

2004

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
LYNNTECH INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
PMVAL8J63516
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): The objective of this proposal is to covalently immobilize an all-carbon nanoparticle that is an excellent photosensitizer (PS) onto biologically inert polymeric backbones for the photodynamic inactivation of pathogens in blood products. The polymers will then be placed in a permeable cartridge and fixed into a flow-through reactor. After filling the reactor with the blood product, the fluid will be circulated and the photocatalyst illuminated with laser light. The illuminated PS catalyzes the formation of singlet oxygen, 1O2*, a reactive species of oxygen that will inactivate pathogens in the blood product. The decontaminated blood product is then simply removed from the reactor, leaving the C60-modified polymer behind. Three types of polymeric backbones will be investigated: 1) hydrophobic polymer, 2) polycationic polymer, 3) non-ionic hydrophilic polymer. The synthetic steps to modify the polymers with C60 start from commercially available polymers and are simple literature procedures. After photocatalyst synthesis and construction of the reactor, the pathogen inactivation system will be evaluated in a series of in vitro experiments to determine the optimal blood product decontamination applications of the new system. Several advantages are expected over conventional homogeneous PS such as methylene blue: 1) there is no post-treatment toxicity because the photocatalyst is heterogeneous and integrated into the reactor structure and upon completion of treatment, the blood product is simply removed from the reactor leaving the catalyst behind, 2) enhanced selectivity of pathogen inactivation is expected due to the polymeric backbone's tunable affinity relative to damage to blood components 3) the nanoparticle PS that will be used has a very high singlet oxygen quantum yield, higher than conventional PS The vision of this project is to introduce a novel, economical system to the blood product market for the inactivation of pathogens in blood products.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

1,079 SBIR/STTR records share this UEI (1988–2025). Reported award amounts total $327,411,388. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Defense, Department of Health and Human Services, National Aeronautics and Space Administration, Department of Energy, National Science Foundation, Environmental Protection Agency

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.